5 Best Breakout Stocks To Buy Now

3. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 44

AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company that develops and manufactures a range of innovative medicines and medical devices. The company operates in more than 100 countries and has a strong focus on research and development, with a number of research facilities around the world. AstraZeneca PLC (NASDAQ:AZN)’s products include prescription medications, over-the-counter products, and medical devices. The company’s products are used to treat a variety of conditions, including cancer, cardiovascular disease, respiratory illness, and infections.

On December 15, 2022, Emmanuel Papadakis, an analyst at Deutsche Bank, increased his price target on AstraZeneca PLC (NASDAQ:AZN) to £13,000 while keeping a Buy rating on the stock. The company’s third-quarter revenue stood at $10.98 billion, beating market expectations by $133.51 million. Its Normalized EPS was reported at $0.84, beating market expectations by $0.09.

44 hedge funds are currently bullish on AstraZeneca PLC (NASDAQ:AZN) as per Insider Monkey’s database. GQG Partners had the leading stake in the company at the end of Q3 2022.